Repeat/cybin announces financing of up to us$500 million aggregate principal amount of convertible debentures

Toronto--(business wire)--cybin inc. (nyse american: cybn) (cboe canada: cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the company has entered into a securities purchase agreement (the “securities purchase agreement”) with high trail special situations llc (“high trail”), pursuant to which the company agreed to sell a.
CYBN Ratings Summary
CYBN Quant Ranking